Core-based scientist specializing in high throughput screening for early drug discovery, target identification and systems biology analysis of cancer

专注于癌症早期药物发现、靶标识别和系统生物学分析的高通量筛选的核心科学家

• 批准号: 10545491
• 负责人: Meng Wu
• 金额: $ 17.96万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-04 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10545491
• 关键词: Core; based; scientist; specializing; throughput

Project Summary: Dr. Meng Wu is Director of the University of Iowa High Throughput Screening Facility (UIHTS), a shared resource of the NCI-designated Holden Comprehensive Cancer Center (HCCC). He is mentored by Dr. George Weiner, Director of the HCCC and PI of Cancer Center Support Grant (CCSG) 5 P30 CA086862-18. Dr. Wu has extensive expertise in high throughput screening, assay development and adaption, fluorescent and label-free detection, the discovery of small-molecule probes and drug leads, high content imaging, and high throughput data analysis; this is evident from his 230 BioAssays in PubChem and 41 publications in PubMed). The UIHTS was established in 2012 by university sponsors including the HCCC. Dr. Wu is the inaugural director of the UIHTS and has overseen the establishment and maintenance of every aspect of the facility, including acquisition of both high throughput and high content imaging equipment, construction of chemical and biological libraries, and establishment of biochemical as well as cell-based standard operating procedures (SOPs). Dr. Wu also streamlined the workflow, from project recruitment, assay development, compound management, high throughput/content screening, data and image analysis, hit-picking and dose-response validation/confirmation, to preliminary datasets for external grant application and final datasets for publication. This effort resulted in integration of the UIHTS into the HCCC as a core facility during its renewal in 2016. Dr. Wu's scientific and administrative leadership of the UIHTS has provided HCCC investigators access to new scientific approaches by a high-throughput platform for integrating robotics, high throughput and high content detection systems, chemical/biologics libraries (small-molecule drugs, arrayed CRISPR gRNAs, and cell lines), data management, and technical expertise. In 2018 alone, the UIHTS core supported 15 NCI-supported projects, among 27 peer reviewed (external funded) cancer research projects, contributing to assay development and high throughput screening. In this NCI R50 proposal, we request salary support for Dr. Wu under Dr. Weiner's mentorship, to support him in the following activities: 1) continued high throughput screening in collaboration with the basic and translational cancer research community, for the discovery of novel probes and therapeutics for cancer patients; 2) development of novel high throughput-compatible assays/technologies (e.g., involving the use of 3D- spheroids, patient-derived organoids, co-culture cell systems) to enable more direct patient-relevant screening approaches; 3) facilitation of systematic, un-biased optimization of synergetic effects of FDA-approved drugs and immune-oncological therapeutics for novel clinical trials; and 4) exploration of the use of patient-derived cells and spheroids in evidence-based precision medicine. Support from the NCI in the form of a Research Specialist Award, together with mentorship and support from the HCCC, will enable Dr. Wu to make a crucial contribution to the overall goals of the HCCC.

项目概要： 博士孟武是爱荷华州大学高通量筛选设施（UIHTS）的主任，该设施是一个共享资源 霍尔顿综合癌症中心（HCCC）。他由乔治韦纳博士指导， HCCC主任和癌症中心支持补助金（CCSG）5 P30 CA 086862 -18的PI。吴博士有广泛的 在高通量筛选、分析开发和适应、荧光和无标记检测方面的专业知识， 小分子探针和药物先导物的发现、高内涵成像和高通量数据分析; 这从他在PubChem上的230个生物测定和在PubMed上的41个出版物中显而易见）。UIHTS成立于 2012年，包括HCCC在内的大学赞助商。吴博士是UIHTS的首任主任， 监督建立和维护设施的各个方面，包括购置两个高 高通量和高含量成像设备，化学和生物图书馆的建设，以及 建立生物化学以及基于细胞的标准操作规程（SOP）。吴博士也 简化了工作流程，从项目招募、检测开发、化合物管理、高 通量/含量筛选、数据和图像分析、命中挑选和剂量反应验证/确认， 初步数据集供申请外部资助，最后数据集供发表。这项努力的成果是 在2016年更新期间，将UIHTS作为核心设施整合到HCCC中。吴博士的科学和 UIHTS的行政领导为HCCC研究人员提供了新的科学方法 通过用于集成机器人、高通量和高含量检测系统的高通量平台， 化学/生物制品库（小分子药物、阵列CRISPR gRNA和细胞系），数据管理， 和技术专长。仅在2018年，UIHTS核心就支持了15个NCI支持的项目，其中27个项目是由NCI支持的。 审查（外部资助的）癌症研究项目，促进分析开发和高通量 筛选在这份NCI R50提案中，我们要求在韦纳博士的指导下为吴博士提供工资支持， 支持他在以下活动：1）继续高通量筛选与基础和 转化癌症研究社区，为癌症患者发现新的探针和治疗方法; 2)开发新的高通量相容的测定/技术（例如，使用3D- 球状体、患者源性类器官、共培养细胞系统），以实现更直接的患者相关筛选 方法; 3）促进FDA批准的药物协同效应的系统性、无偏倚优化 和免疫肿瘤治疗新的临床试验;和4）探索使用患者来源的细胞 和球状体在循证精准医学中的应用。NCI以研究专家的形式提供支持 胡博士的得奖，加上香港基督教协进会的指导和支持，将使他能够作出重要贡献 符合HCCC的总体目标。